Arrowhead Pharmaceuticals highlighted its ongoing transition toward commercial operations while maintaining a strong research and development core during a recent industry conference.
At the Bank of America Global Healthcare Conference on May 11, chief executive Christopher Anzalone described the company as an 'And company' rather than an 'Or company.' He emphasized that building a commercial force has been a major shift but remains successful without slowing the firm's core research efforts, which have in fact accelerated.